1. Home
  2. TSI vs BNR Comparison

TSI vs BNR Comparison

Compare TSI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TCW Strategic Income Fund Inc.

TSI

TCW Strategic Income Fund Inc.

HOLD

Current Price

$4.60

Market Cap

221.7M

Sector

Finance

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$16.66

Market Cap

252.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSI
BNR
Founded
1987
2014
Country
United States
China
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
221.7M
252.7M
IPO Year
1995
2019

Fundamental Metrics

Financial Performance
Metric
TSI
BNR
Price
$4.60
$16.66
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
251.1K
15.6K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
7.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$136.32
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.57
$2.18
52 Week High
$5.06
$41.72

Technical Indicators

Market Signals
Indicator
TSI
BNR
Relative Strength Index (RSI) 36.37 32.83
Support Level $4.58 $15.64
Resistance Level $4.96 $24.23
Average True Range (ATR) 0.04 2.01
MACD 0.01 -0.74
Stochastic Oscillator 23.68 18.33

Price Performance

Historical Comparison
TSI
BNR

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

Share on Social Networks: